[{"orgOrder":0,"company":"Kincell Bio","sponsor":"Imugene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Agreement","leadProduct":"Azercabtagene Zapreleucel","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kincell Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kincell Bio \/ Imugene","highestDevelopmentStatusID":"7","companyTruncated":"Kincell Bio \/ Imugene"}]

Find Clinical Drug Pipeline Developments & Deals by Kincell Bio

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : Under the agreement, Kincell will manufacture Imugene’s Azer-cel (azercabtagene zapreleucel), an off-the-shelf (allogeneic) cell therapy CAR T drug, to support ongoing clinical trials.

                          Brand Name : PBCAR0191

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          April 16, 2024

                          Lead Product(s) : Azercabtagene Zapreleucel,Cyclophosphamide,Fludarabine Phosphate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Imugene

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank